Bristol-Myers Squibb

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. 

CEO
Christopher S. Boerner
CEOChristopher S. Boerner
Employees
32,500
Employees32,500
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
1933
Founded1933
Employees
32,500
Employees32,500

BMY Key Statistics

Market cap
136.89B
Market cap136.89B
Price-Earnings ratio
14.42
Price-Earnings ratio14.42
Dividend yield
3.83%
Dividend yield3.83%
Average volume
9.20M
Average volume9.20M
High today
$67.55
High today$67.55
Low today
$65.13
Low today$65.13
Open price
$65.73
Open price$65.73
Volume
6.83M
Volume6.83M
52 Week high
$68.64
52 Week high$68.64
52 Week low
$42.52
52 Week low$42.52

Stock Snapshot

Bristol-Myers Squibb(BMY) stock is priced at $67.35, giving the company a market capitalization of 136.89B. It carries a P/E multiple of 14.42 and pays a dividend yield of 3.83%.

During the trading session on 2026-08-21, Bristol-Myers Squibb(BMY) shares reached a daily high of $67.55 and a low of $65.13. At a current price of $67.35, the stock is +3.4% higher than the low and still -0.3% under the high.

Trading activity shows a volume of 6.83M, compared to an average daily volume of 9.2M.

The stock's 52-week range extends from a low of $42.52 to a high of $68.64.

The stock's 52-week range extends from a low of $42.52 to a high of $68.64.

BMY News

TipRanks 5h
Bristol-Myers Squibb Adds Early Alzheimer’s Antibody To Its Long-Term Growth Story

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter,...

MarketWatch 1d
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors - MarketWatch

...

Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors - MarketWatch
TipRanks 1d
Bristol‑Myers Squibb Advances Navlimetostat Metabolism Study, Signaling Steady Pipeline Progress

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter,...

Analyst ratings

58%

of 31 ratings
Buy
35.5%
Hold
58.1%
Sell
6.5%

More BMY News

24/7 Wall St. 1d
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO

Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO By Trey Thoelcke Published Aug 20, 10:40AM EDT Quick Read SPTX's Glyph prodrug pl...

Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO
TipRanks 1d
Bristol-Myers Squibb: Late-Stage Pipeline Catalysts Support Buy Rating and Unchanged $80 Price Target

Michael Yee, an analyst from UBS, maintained the Buy rating on Bristol-Myers Squibb. The associated price target remains the same with $80.00. Unlock powerful...

Simply Wall St 2d
Is Bristol-Myers Squibb Fully Priced As FDA Approval And $2.3b Expansion Lift Outlook?

Bristol-Myers Squibb (BMY) is in focus after two related announcements. The FDA granted accelerated approval for its new multiple myeloma drug ZENBEXUS, and the...

Is Bristol-Myers Squibb Fully Priced As FDA Approval And $2.3b Expansion Lift Outlook?
Simply Wall St 3d
Bristol Myers Squibb Stock May Be 46% Below Fair Value As FDA Approval Lands

Bristol-Myers Squibb stock has delivered a 40.6% 1 year return, while both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currentl...

Bristol Myers Squibb Stock May Be 46% Below Fair Value As FDA Approval Lands

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.